AptarGroup sees Q3 EPS $1.53-$1.61, consensus $1.65

The company states: “Looking ahead to Q3, we expect a solid quarter with continued strength in Pharma, particularly in Injectables, driven by rising demand for higher value elastomeric components fueled by growth in biologics, GLP-1 therapies, and Annex 1 compliance requirements. We anticipate challenges as naloxone sales begin to normalize after a period of rapid growth. Additionally, we expect elevated levels of cough and cold inventory in Europe to persist through the quarter. We anticipate modest Q3 contributions from our Closures and Beauty segments. Across all segments, we remain focused on cost discipline. In the face of external headwinds, our pipeline and industrialized capabilities position us well for sustained growth.”